**Financial Highlights:** Krsnaa Diagnostics reported robust Q1 FY26 results: Revenue grew 13% YoY to ₹193 Cr, EBITDA increased 19% YoY to ₹52.4 Cr (27% margin), and PAT rose 15% YoY to ₹20.5 Cr.

Served ~5 million patients and performed ~16 million tests. **Strategic Initiatives & Growth Drivers:** Growth stemmed from new center operationalization and efficiency.

Retail expansion is key, with touchpoints now at 2,414 and retail revenue reaching ₹11.8 Cr.

Future targets include 200+ CT/MRI and 5,000+ pathology collection centers, leveraging long-term PPP contracts. **Business Developments:** The company is expanding its integrated radiology, pathology, and tele-radiology services, boosting NABL/NABH accredited facilities.

It's broadening its diagnostic test portfolio and strengthening B2B collaborations. **Market Position & Competitive Advantage:** Krsnaa is a leading integrated diagnostic provider excelling in the PPP model across 18 states.

Its unique advantage is offering quality services up to 70% cheaper than peers at healthy margins, supported by its accredited tele-radiology hub. **Investor Implications:** Consistent financial performance, aggressive expansion, and a cost-efficient model indicate positive growth potential.